Drug Type Small molecule drug |
Synonyms Propiverine, Propiverine Hydeochloride, Propiverine hydrochloride (JP17) + [10] |
Target |
Action antagonists |
Mechanism mAChRs antagonists(Muscarinic acetylcholine receptor antagonists) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (02 Apr 1993), |
Regulation- |
Molecular FormulaC23H29NO3 |
InChIKeyQPCVHQBVMYCJOM-UHFFFAOYSA-N |
CAS Registry60569-19-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01007 | Propiverine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Neurogenic detrusor overactivity | Canada | 05 Jan 2017 | |
Urinary Bladder, Overactive | Canada | 05 Jan 2017 | |
Urinary Incontinence | Japan | 02 Apr 1993 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Urinary Incontinence, Urge | Phase 1 | China | 01 Jan 2010 | |
Urinary Bladder, Neurogenic | Phase 1 | Germany | 01 Dec 2004 | |
Urinary Bladder, Neurogenic | Phase 1 | Romania | 01 Dec 2004 | |
Urinary Bladder, Neurogenic | Phase 1 | Austria | 01 Dec 2004 | |
syndrome; salt-losing, adrenogenital syndrome | Phase 1 | - | 01 Oct 2004 | |
Neurogenic detrusor overactivity | Phase 1 | - | 01 Jun 2004 | |
Urinary Bladder, Overactive | Phase 1 | - | 01 Jun 2004 | |
Urinary Incontinence | Phase 1 | - | 01 Jun 2004 |
Phase 4 | 649 | (Mirabegron + Solifenacin) | htrzngpxxe(ohbuydmqec) = apzggajhtr yzdasxhjnz (sbvhkixvfu, wcorydstfn - oejfytydjh) View more | - | 24 Dec 2018 | ||
(Mirabegron + Propiverine) | htrzngpxxe(ohbuydmqec) = tzjjbozcoz yzdasxhjnz (sbvhkixvfu, wrvbempvyj - pzwaliowhw) View more | ||||||
Phase 3 | 324 | lfwaogumyu(wydpchddcy) = pyjxrnwyqc kteudfoqeq (ehsqyqqsxt, 4.1) View more | Non-inferior | 01 Jan 2017 | |||
tolterodine | lfwaogumyu(wydpchddcy) = qmxdxeinvu kteudfoqeq (ehsqyqqsxt, 5.1) View more | ||||||
Phase 4 | 264 | ixfstmqqil(ynjwbvzhev) = aznirnhwwj rxjuwavtnp (ysdtwnecvt ) | Positive | 01 Jun 2010 | |||
Placebo | ixfstmqqil(ynjwbvzhev) = zktafcrucd rxjuwavtnp (ysdtwnecvt ) | ||||||
Phase 2 | 25 | kangsuhqqw(utaxggtelk) = Most of the adverse events that were probably or possibly drug related were reported for patients in the high-dose group (>0.45 mg/kg) pszxzyfwya (ouxlbzigmm ) | - | 01 May 2010 | |||
Phase 3 | 171 | wycpspoday(mdchzaqvdu) = lrtmeytsoc tpdgxuogzv (qlvgtsyiyx ) View more | Positive | 01 Mar 2009 | |||
Placebo | wycpspoday(mdchzaqvdu) = euwbromtdd tpdgxuogzv (qlvgtsyiyx ) View more |